Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients

British Journal of Haematology

Volumn 118, Issue 3, 2002, Pages 786-790

  Cervantes, Francisco ^a,b   Alvarez Larrán, Alberto ^a   Talarn, Carme ^a   Gómez, Marta ^a   Montserrat, Emilio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Essential thrombocythaemia; Idiopathic myelofibrosis; Myelofibrosis with myeloid metaplasia; Myelofibrotic transformation

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CHROMOSOME ABERRATION; CLINICAL FEATURE; DISEASE COURSE; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; PROBABILITY; PROMYELOCYTE; SCHOOL CHILD; SPLENOMEGALY; STATISTICAL ANALYSIS; SYMPTOM; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PLATELET COUNT; PROBABILITY; RISK ASSESSMENT; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0036041873     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03688.x     Document Type: Article

References (25)

1. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
2. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients
3. Clonality markers in polycythemia and primary thrombocythemia
4. Identification of 'short-lived' and 'long-lived' patients at presentation of primary myelofibrosis
5. Essential thrombocythemia: A retrospective study on the clinical course of 100 patients
6. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
7. Progression of essential thrombocythemia to blastic crisis via idiopathic myelofibrosis
8. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
9. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation
10. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
11. Nonparametric estimation from incomplete observations
12. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia
13. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia
14. Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group
15. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
16. Primary thrombocythaemia: Diagnosis and management
17. Idiopathic myelofibrosis: Pathogenesis, natural history and management
18. Life expectancy of patients with chronic non-leukemic myeloproliferative disorders
19. Recent progress in the pathogenesis and management of essential thrombocythemia
20. Primary thrombocythemia
21. Chronic idiopathic myelofibrosis
22. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis
23. Primary thrombocythaemia treated with busulphan
24. Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin
25. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors